An interventional study of Dexmedetomidine group (D group) and Ketamine group (K group) in Emergence Delirium, Anesthesia, sponsored by Zagazig University. Active, not recruiting at 1 site in Egypt. Open to participants aged 3 Years to 5 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-27.
Sponsored by Zagazig University · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 83 studies testing dexmedetomidine in Emergence Delirium — 31 open to participants now, 32 under way, 2 of them phase 3. Dexmedetomidine · Emergence Delirium.
Among the 83 studies testing dexmedetomidine in Emergence Delirium, this one is the 51st largest by planned enrollment, is one of 16 that started in 2026, is one of 27 with no phase, reaches primary completion later than 21 of the 31 other live ones, and was the 63rd registered.
753 studies on the registry are indexed under Emergence Delirium; 261 are open to participants now.
Browse Emergence Delirium studies →31 of the 83 studies testing dexmedetomidine in Emergence Delirium are open now, in 10 countries. Recruiting first, the newest first:
Pakistan Institute of Medical Sciences · Sites in Pakistan
Ages 2–12 · Healthy volunteers
Boston Children's Hospital · Sites in United States
Ages 1–12
Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital · Sites in Turkey
Ages 2–10
Bach Mai Hospital · Sites in Vietnam
Ages 18–65
Kasr El Aini Hospital · Sites in Egypt
Ages 2–6
By country, each count listing its studies:
Dexmedetomidine: first FDA approval 1999 (PRECEDEX), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 141 Emergence Delirium studies recruiting now, 78 (55%) set no upper age limit and 43 (30%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.
This study: 3 Years to 5 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
83 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 11 · Phase 3 13 · Phase 4 31
First in 2006; this study’s year is marked. 16 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 92 is below the median of 120 across 467 interventional studies indexed under Emergence Delirium.
Median enrollment 100 across the 83 interventional studies. Of the 38 that completed or were terminated, 10 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 83 have an industry lead sponsor. The 10 most frequent:
Zagazig University is the lead sponsor of 462 studies on the registry; 78 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Zagazig University has 3 studies filed under Emergence Delirium — fewer than ten, so there is no comparison to draw.
13 of the studies testing dexmedetomidine in Emergence Delirium that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07538284Phase 3Sixth Affiliated Hospital, Sun Yat-sen UniversityMInimizing Delirium With Nasal Dexmedetomidine-InducEd Sleep (MIDDIES) | 2026-12-31 |
| NCT07810556Phase 3Assiut UniversityIntrathecal Dexmedetomidine and Postoperative Delirium in Elderly Hip Fracture Surgery | 2027-10 |
| NCT07519863Ain Shams UniversityThe Effect of Dormicum-Ketamine Versus Dexmedetomidine on Emergence Delirium During Deep Sedation in Paediatric Burn Patients | 2026-11 |
| NCT07799311Pakistan Institute of Medical SciencesComparing the Efficacy of Propofol and Dexmedetomidine in Prevention of Emergence Agitation After Sevoflurane Anesthesia in Children | 2026-11-28 |
| NCT07601698Sohag UniversityDexmedetomidine vs Propofol-lidocaine Mixture in Preventing the Post Operative Emergence Agitation Following Sevoflurane Anasthesia | 2026-11-30 |
Add all 13 to your calendar (.ics) → With an account.
Among the 83 studies testing dexmedetomidine in Emergence Delirium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Emergence delirium (ED) was first described by Eckenhoff and colleagues in the 1960s and is defined in pediatric anesthesia as 'dissociated state of consciousness in which child is irritable, uncompromising, uncooperative, incoherent, and inconsolably crying, moaning, and kicking or thrashing. The commonly reported incidence of postoperative ED in pediatric patients especially with the use of sevoflurane or desflurane was from 10% to 80% during their presence in the post-anesthesia care unit. This side effect of general anesthesia causes distressing for parents and staff and may cause parental dissatisfaction with their child's care. Children during postoperative ED have the risks of injuring themselves or their caregivers, disruption of surgical repair, operative site bleeding, removing Intravenous (iv) lines or drains and increasing pain. This behavior may require more nursing supervision, overloading nursing resources. Although postoperative ED episodes are of short duration, their prevention is essential. Children experiencing postoperative ED may exhibit new-onset maladaptive behavioral abnormalities in the postoperative period such as enuresis, night-time crying, and separation anxiety, up to 14 days post-surgery.
The risk factors to postoperative ED are patients' characters (preschool age and preexisting behavior), the surrounding environment as parental anxiety, type of anesthesia (volatile anesthetics) as sevoflurane or halothane and the type of surgery as tonsillectomy, adenoidectomy, and strabismus surgery which is one of the most commonly undertaken surgeries in pediatric patients. It may cause visual disturbance in the recovery phase, which can result. In order to diagnose ED, the presence of pain during recovery from general anesthesia must be ruled out because it leads to a change in behavior that resembles delirium. Fortunately, one of the advantages of using the Pediatric Anesthesia Emergence Delirium (PAED) scale is its ability to distinguish between the ED and the change in behavior resulting from pain, because it focuses on changes in awareness and knowledge that are not changed by pain. Prophylactic drugs against the occurrence of postoperative ED include the adjuvant use of α2 adrenoreceptor agonists such as dexmedetomidine, ketamine, midazolam, propofol, and fentanyl. The use of these drugs with them adverse effects should be weighed against the fact that postoperative ED is a self-limited disorder. Dexmedetomidine is a highly selective α2-adrenergic receptor agonist that is associated with sedative and analgesic sparing effects. It is commonly used for prevention of emergence delirium and agitation, perioperative sympatholysis, cardiovascular stabilization, and preservation of respiratory function. Ketamine is a dissociative anesthetic. Its mechanism of action is mainly via a noncompetitive antagonism of the N - methyl - D - aspartic acid (NMDA) receptor. It also targets other receptors, such as a - amino - 3 - hydroxy - 5 - methyl - 4 - isoxazolepropionic acid (AMPA) receptors, and has additional acts as an agonist of the sigma 1 receptor. It is commonly used for acute pain management, chronic pain management, prevention of ED, and postoperative nausea and vomiting. Midazolam is short acting benzodiazepine which is central nervous system depressant. It is commonly used for premedication during pediatric anesthesia, for prevention of emotional distress and ED due to its sedative and anxiolytic properties, additionally it used for reduction of the analgesic requirement and to prevent postoperative nausea and vomiting
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
patients will receive 5ml of normal saline intravenous10 min before the end of the surgical procedure as placebo.
Other: 5ml of normal saline
patients will receive intravenous dexmedetomidine (0.25 μg/kg diluted with normal saline to a volume of 5 ml solution) 10 min before the end of the surgical procedure.
Drug: Dexmedetomidine group (D group)
patients will receive intravenous ketamine (0.25mg/kg diluted with normal saline to a volume of 5 ml solution) 10 min before the end of the surgical procedure.
Drug: Ketamine group (K group)
patients will receive intravenous midazolam (0.05 mg/kg diluted with normal saline to a volume of 5 ml solution) 10 min before the end of the surgical procedure.
Drug: Midazolam group (M group)
patients will receive intravenous dexmedetomidine (0.25 μg/kg diluted with normal saline to a volume of 5 ml solution) 10 min before the end of the surgical procedure.
patients will receive intravenous ketamine (0.25mg/kg diluted with normal saline to a volume of 5 ml solution) 10 min before the end of the surgical procedure.
patients will receive intravenous midazolam (0.05 mg/kg diluted with normal saline to a volume of 5 ml solution) 10 min before the end of the surgical procedure.
patients will receive 5ml of normal saline intravenous10 min before the end of the surgical procedure as placebo.
the incidence and severity of ED using the Pediatric Anesthesia Emergence Scale (PAED) Scale.
the incidence and severity of ED using the Pediatric Anesthesia Emergence Scale (PAED) Scale.
Time frame: preoperative, baseline, PACU, 10, 20, 30 mins postoperative , perioperative
recovery time. postoperative pain severity
Recovery time. IV. Post operative pain severity: will be assessed upon arrival to PACU, then at 10, 20, 30 min, and finally upon discharge from it. V. Hemodynamic and SpO2 changes: MAP, HR, and SpO2 will be measured the night before surgery as baseline, then intraoperative immediately before and at 5, 10, 20, 30 min after study drug administration. In the PACU, these parameters will be recorded upon arrival to PACU and then at 10, 20 min and finally upon discharge from PACU. VI. Time to discharge from PACU. VII. The degree of parents' satisfaction. VIII. The associated side effects: such as bradycardia, hypotension, peripheral blood oxygen desaturation vomiting, and allergy to the study drugs
Time frame: preoperative as baseline and upon arrival to PACU, then 10, 20, and 30 minutes after admission, perioperative
Plan to share: Yes — planned after the completion of the study and publication
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code
Time frame: planned after the completion of the study and publication
Access criteria: principal investigator
Started Jan 2026 (actual). Primary completion is estimated for Jan 2027, 12 months after the start.
Of 186 non-industry interventional studies with no phase under Emergence Delirium, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 36. This study's planned 12 months is below that.
Counting every sponsor, half of 186 studies reached it within 19 months; a quarter within 7 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Dexmedetomidine · Ketamine · Midazolam